Artificial intelligence has the potential to transform cancer research. But AI is only as powerful as the data behind it. The Cancer Research Institute's Discovery Engine is building…
Yu-Wei Chen, MD, MS, Assistant Professor of Medicine, University of California, San Diego, La Jolla, California, reviews later-line treatment strategies for advanced renal cell carcinoma (RCC) in the…
Giuseppe Procopio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy, highlights a radiomics analysis of progression-free survival from the multicenter Italian MeetUro 31 translational study…
Tenesha Wallace Hood, MA, of the National Eczema Association explains how where patients live shapes atopic dermatitis care access, based on findings from the State of AD 2026…
Douglas DiRuggiero, DMSc, MHS, PA-C, shares how oral and targeted therapies in psoriasis are discussed at Horizons in Advanced Practice and what he expects across inflammatory skin disease…
Topical corticosteroids remain a cornerstone of atopic dermatitis care, but steroid phobia and a growing roster of nonsteroidal agents are reshaping how clinicians use them. On this episode…
Why can’t some Medicare patients get advanced therapy for skin disease, even after they’ve failed standard topicals? In this interview from the 2026 Horizons in Advanced Practice meeting…
Patients with moderate-to-severe atopic dermatitis who respond early to nemolizumab (Nemluvio) tend to keep improving with continued treatment. That finding comes from a post hoc analysis of the…
Exosomes in dermatology are moving closer to a regulatory pathway, and a new remibrutinib label update is changing how clinicians approach symptomatic dermographism. Todd Schlesinger, MD, shares the…
Atopic dermatitis late-breakers from EADV 2026 in Vienna are the focus of this Dermatology Times interview with Christopher Bunick, MD, PhD, associate professor of dermatology at Yale School…
